The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus - Forst, T; Uhlig-Laske, B; Ring, A (Diabetes Obes Metab, 2011)
et al.